We report the influence of the Oncotype DX colon assay results on patient treatment decisions, physician confidence, and concordance between physicians and patients. A total of 221 consecutive patients were enrolled, and tumor specimens were assessed. Before and after receiving the assay results, the patients and physicians completed surveys that included their treatment preferences and other factors. Knowledge of the assay results was associated with improved patientephysician concordance and confidence. Background: The Oncotype DX colon cancer assay is a validated predictor of recurrence risk in patients with resected stage II colon cancer. We previously reported that Oncotype DX led to a change in treatment recommendations for 45% of patients with T3 mismatch repair proficient (MMR-P) stage II tumors in a prospective study. In the present study, we report the assay's influence on patient treatment decisions, physician confidence, concordance between physicians and patients, and patient decisional conflict. Patients and Methods: Consecutive patients with resected stage IIA colon cancer were enrolled. The tumor specimens were assessed using a 12-gene assay (reverse transcription-polymerase chain reaction) and by immunohistochemistry for MMR. Before and after receiving the results, the patients completed surveys that included their treatment preference, their current and preferred roles in treatment decision-making, and indicators of decisional conflict. Physicians completed similar pre-and postassay surveys. Results: Of 221 patients enrolled, 139 T3 MMR-P patients were evaluable for the patient-reported analyses and 150 patients were evaluable for the physician-reported analyses. Before the assay, 46% of the patients chose observation, 3% 5-fluorouracil, 7% oxaliplatin, 4% other, and 41% were undecided. After the assay, 75% chose observation, 12% 5-fluorouracil, 11% oxaliplatin, and 2% other. After the assay, 94% of the defined treatment decisions were concordant between patients and physicians compared with 60% before the assay. Physicians reported the assay influenced their treatment decisions and increased confidence in their treatment recommendations for 69% and 84% of patients, respectively. Most patients (86%) reported that the assay influenced their treatment decisions. Patient decisional conflict was significantly lower after learning the assay results (P < .001). Conclusion: In the present prospective study, knowledge of the 12-gene assay results influenced treatment decisions for most patients and physicians, increased physician confidence, improved the concordance between patients and physicians, and decreased patient decisional conflict.
Introduction
Each year, worldwide, > 1,350,000 people are diagnosed with colorectal cancer (CRC), and approximately 700,000 men and women die of the disease. 1 Among patients diagnosed with stage II colon cancer, 75% to 80% will be cured by surgical resection and have a low absolute benefit from adjuvant chemotherapy. 2 A small subset of these patients will benefit from the addition of 5-fluorouracil (5-FU) therapy, with or without oxaliplatin. 3, 4 However, the identification of this subset of patients has been challenging. The Oncotype DX colon cancer assay (Genomic Health, Inc, Redwood, CA) is a 12-gene prognostic assay that measures gene expression in formalin-fixed paraffin-embedded colon cancer tissue by quantitative reverse transcription-polymerase chain reaction and generates a recurrence score result that provides an estimate of the risk of recurrence. In the assay development study, the relationship between tumor gene expression and recurrence was evaluated in a pooled analysis of 1851 patients with stage II and III enrolled in 4 independent National Surgical Adjuvant Breast and Bowel (NSABP) clinical trials and a Cleveland Clinic study, in which patients were treated with surgery plus adjuvant 5-fluorouracil plus leucovorin (5-FU/LV) or surgery alone. 5 A total of 48 genes were significantly associated with the risk of recurrence. Of these, 7 recurrence genes and 5 reference genes were selected to stratify the patients into groups with a low, intermediate, and high likelihood of recurrence. 5 The 12-gene prognostic assay was subsequently validated in 4 large independent studies that included > 3000 patients with stage II and III colon cancer 6-9 and, hence, achieved level IB evidence. 10 The first validation study used tumor samples from 1436 patients with stage II disease enrolled in the Quick and Simple and Reliable (QUASAR) trial of adjuvant 5-FU/LV versus surgery alone to demonstrate that the 12-gene recurrence score result is a significant predictor of recurrence. 6 Next, the assay was validated in 690 patients with stage II disease enrolled in the Cancer and Leukemia Group B 9581 clinical trial. 7 In addition, the NSABP group validated the assay in 892 patients with stage II and III disease treated with 5-FU chemotherapy with or without oxaliplatin enrolled in the C-07 trial, in which the potential utility of the assay was demonstrated for both stage III and stage II patients. 8 Finally, the 
Decision Impact Study
The decision impact clinical trial was conducted to evaluate the effect of the recurrence score result on joint patient and physician treatment decisions among patients with T3 mismatch repair proficient (MMR-P) stage II colon cancer. Before and after the prognostic assay results were provided, the patients and physicians separately completed questionnaires related to the planned treatment, degree of confidence in the chosen treatment plan, and utility of the assay in making the treatment decision. We previously reported primary physician-based analyses, in which we showed shown that knowledge of a patient's recurrence score result led to a 45% change in physician treatment recommendations (95% confidence interval [CI], 36%-53%) among 141 evaluable patients. 11 Furthermore, we found that lower recurrence score values were associated with de-escalation of physicians' recommended treatment strategies (eg, from chemotherapy before the result to observation alone after the result), and higher scores were associated with escalated recommendations (eg, from observation to chemotherapy; P ¼ .01). In the present report, we provide the trial's other prospective analyses on the pre-versus postassay patient-reported and physician-reported outcomes, including the influence of the recurrence score result on patients' treatment decision-making and decisional conflict, confidence in treatment recommendations, and shared decision-making between patients and physicians.
Patients and Methods

Patient and Physician Data Collection
In the present prospective multicenter study, 221 consecutive patients with stage IIA (T3N0) cancer were enrolled by 105 physicians across 17 academic and community sites within the Mayo Clinic Cancer Research Consortium network. The treating physicians were not required to have previous experience with Oncotype DX and received training on using the assay, which consisted of 
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Effect of Colon Assay on Patient Treatment Decisions and Physician Confidence reviewing the product materials and mock cases. To be eligible for study participation, patients agreed to both MMR testing by immunohistochemistry and evaluation using the Oncotype DX colon cancer assay. The patient and physician materials emphasized the merely prognostic (rather than predictive) nature of the assay. Before and after obtaining the recurrence score results, the patients and physicians independently completed surveys that included the planned treatment (ie, observation alone vs. 5-FU monotherapy vs. 5-FU plus oxaliplatin). The baseline patient survey also included "undecided" as a treatment option. The physicians also completed pre-and postassay surveys indicating whether they were confident in their treatment decisions, whether they believed the Oncotype DX colon cancer assay would (or did) provide additional clinically relevant information, and whether the assay results had directly influenced their treatment recommendations. Before and after learning their recurrence score results, the patients completed the decisional conflict scale (DCS), 12 a clinically validated 16-item instrument used to assess the perceptions of personal uncertainty in making decisions about health care treatment options and satisfaction with treatment decision-making. All patient and physician surveys were independently completed in the physician's office directly after each patient's appointment. For analysis purposes, observation, 5-FU alone, and 5-FU plus oxaliplatin were described as definitive treatment decisions or recommendations, although the physicians and patients were allowed to specify other treatment plans.
Statistical Analysis
All analyses were prespecified in a statistical analysis plan. The distribution of physician treatment recommendations and distribution of patient treatment preferences (after discussion with physicians) both before and after the recurrence score result were reported and analyzed for patientephysician concordance. Other questionnaire items related to physician and patient confidence in the assay, its influence on the patient's treatment decision process, and patients' actual versus preferred roles in their own treatment decisions were summarized descriptively.
Patients' self-reported descriptions of their actual and preferred roles in the treatment decision-making process were recorded on ordinal scales (ranging from patient-led decision-making to physician-led decision-making) before and after the assay results were provided, such that they could be compared between time points. In addition, each patient completed the DCS before and after knowledge of their recurrence score result. For each time point, an overall DCS score and 5 subscores from a 16-item questionnaire were calculated. The subscores were calculated only if ! 2 nonmissing responses were present in the corresponding category, in accordance with the recommendations associated with the tool. 12 A total score, derived as the weighted average of the subscores, was calculated only when all 5 subscores were present. The mean changes for the total score and 5 subscores from before the assay to after were calculated, such that a mean decrease reflected less (or improved) decisional conflict. The pre-and postassay DCS total scores were statistically compared using a paired sample t test, after confirming the approximate normality of the scores.
Owing to the known relationship between MMR status and prognosis for stage II colon cancer, in which patients with MMRdeficient tumors have a better prognosis than patients with MMR-P tumors and are often treated without adjuvant chemotherapy, 13 the present analyses were restricted to patients with T3 MMR-P tumors. Missing data were excluded from the corresponding analyses.
Results
Of the 221 enrolled patients, responses from 139 and 150 patients with MMR-P tumors were evaluable for analyses of the patient-and physician-reported outcomes, respectively (Table 1) . Paired treatment recommendations were available for 139 patients and their physician before the assay and for 138 patients and their physicians after the assay. The characteristics of the patients enrolled and evaluable for these analyses are listed in Table 2 ; the eligibility and other trial details have been previously described. 11 
Patient Treatment Decisions
Similar to the physicians' decisions, the patients' decisions regarding treatment showed changes from before to after having knowledge of the assay results. Before the assay results were 
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available, 64 patients (46%) selected observation alone, 13 (9%) selected chemotherapy, 5 (4%) chose other, and 56 (41%) were undecided. Of the 82 patients with defined (ie, excluding "undecided") treatment decisions before the assay, 27 (33%; 95% CI, 23%-43%) changed their decisions after viewing the assay results (Table 3) , either toward an escalation or a reduction of treatment intensity. Of the 76 patients with definitive pre-and postassay treatment decisions (ie, excluding both "undecided" and "other"), 22 patients (29%; 95% CI, 19%-41%) changed their treatment recommendations after learning the assay results. Of these, 9 (41%) decreased their planned treatment intensity, and 13 (59%) increased their treatment intensity. Most patients who were undecided before the assay (42 of 56; 75%) chose observation after the assay results.
PatientePhysician Treatment Decision Concordance
Of the 82 patient and physician pairs with defined preassay treatment decisions (ie, excluding patient selections in the "undecided" category), 49 (60%) of the treatment decisions between patients and physicians were concordant (Table 4) . After receiving and discussing the assay results, the patients and physicians largely indicated preferences for the same treatment, with 130 of 139 patient-physician pairs (94%) reporting concordant treatment decisions (Table 5) .
Patient Decisional Conflict
A total of 135 patients completed the pre-and postassay DCS instruments; thus, the effect of the assay results could be evaluated. Differences in the mean DCS scores are listed, overall and within individual subscales, in Table 6 . Statistically significant decreases in patient decisional conflict were observed overall (P < .001) and within each of the 5 subscales: effective decision (P ¼ .001), informed (P < .001), support (P ¼ .005), uncertainty (P < .001), and values clarity (P < .001).
Patient Roles in Treatment Decision-Making
At baseline, the patients reported a high level of concordance (90%) between the role they believed they were actually playing and their preferred role in treatment decision-making, with most patients preferring some degree of collaboration (equal or somewhat patient-or physician-led) with their physician (Table 7) . The postassay concordance between the patients' actual and preferred roles was similarly high (88%), with both patients and physicians preferring some degree of collaboration (Table 8) . When the patients' actual roles were compared before and after the assay, 58 of the 136 responses (43%) changed, with 33 patients (24%) reporting an increased patient role and 25 (18%) a decreased role ( Table 9 ). The patients' preferred roles also changed after the assay (58 of 136 responses; 43%), with 37 patients (27%) desiring an increased role relative to their physicians and 21 patients (15%) a lesser role (Table 10 ).
Influence of Oncotype DX Colon Cancer Assay on Patient and Physician Treatment
We previously reported that knowledge of a patient's recurrence score result led to a 45% change in physician treatment recommendations (95% CI, 36%-53%). 11 Specifically, lower recurrence score results were associated with de-escalation of physicians' recommended treatment strategies (eg, from chemotherapy before the assay result to observation alone after the assay), and higher scores were associated with escalated recommendations (eg, from observation to chemotherapy; P ¼ .01). The distribution of the physicians' and patients' postassay questionnaire responses regarding the utility and influence of the assay are listed in Table 11 . Overall, physicians reported that they were more confident in their treatment recommendations after ordering the assay for 126 of 150 patients (84%). Also, for a similarly high percentage (86%) of patients, the physicians agreed that the assay provided additional clinically relevant information. The physicians reported that the assay influenced their treatment recommendations for 103 of the 150 patients (69%). Similarly, 118 of 138 patients (86%) reported that their treatment decisions were influenced by the assay results.
Discussion
For early-stage colon cancer, an increasing number of prognostic tools are available to help predict the risk of recurrence. These tools include clinical calculators and recurrence assays using gene expression profiles. In a recent randomized study involving patients with breast or colon cancer, the use of decision aids was shown to decrease anxiety.
14 In our study, the patients with confirmed T3
MMR-P stage II colon cancer were prospectively enrolled to evaluate the effect and utility of the Oncotype DX colon cancer assay on joint patient and physician treatment decisions and patient-reported roles in treatment decision-making. We found that the prognostic assay results increased physicians' confidence in their treatment recommendations for 126 of 150 patients (84%) and provided additional clinically relevant information for 129 of 150 patients (86%). Most patients (85%) further reported that the assay influenced their treatment decisions. After the assay, 129 of 135 definitive treatment decisions (96%; observation, 5-FU, or 5-FU plus oxaliplatin) were concordant between the patients and physicians compared with 49 of 74 definitive decisions (66%) before the assay. Also, 24 of the 25 preassay discordances between patients and physicians reflected a tendency for the physicians to be more inclined to initially recommend chemotherapy and for patients to prefer observation (Table 4) . Among the patients with definitive pre-and postassay decisions, 22 of 76 decisions (29%) changed after the assay, with the intensity of treatment decreasing for 9 patients (12%) and increasing for 13 (17%). Although the patients reported uniformly high concordance between the actual and desired roles in treatment decision-making at both time points, these roles changed for approximately 43% of the patients from before the assay to after the assay, with most patients favoring an increased role in their treatment decision-making compared with at the diagnosis. Patient decisional conflict was also significantly reduced after the patients and physicians knew the assay results (P < .001).
In a setting of uncertainty regarding the potential benefit of adjuvant chemotherapy, the results of the present study emphasize the relevance of both effective communication and the use of decision aids. Previous studies evaluating the importance of providerepatient communication have demonstrated its positive effect on treatment decision-making and outcomes for patients with cancer. These outcomes include a greater level of satisfaction with Data presented as n (%). The bold figures along the diagonal denote agreement between pre-assay and post-assay patient decisions regarding treatment, while off-diagonal italicized figures indicate a change in patient treatment preference from pre-to post-assay. Table 8 
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the treatment decisions and a greater level of adherence to a specific plan of care. 15 This is particularly important in the setting of adjuvant therapy for stage II colon cancer for which the risk/benefit ratio is less well defined. Previous retrospective studies have shown that when patients with cancer are more actively engaged in decision-making, they experienced a greater level of feeling informed and a greater level of satisfaction with their plan of care.
15
In the current era of patient-centered communication and shared decision-making, providers are expected to more actively engage patients in decisions, using their own medical knowledge and experience to guide such conversations. The process of shared decision-making is dynamic. Previous research has shown that physicians making recommendations in the setting of serious health issues such as colon cancer are less likely to be risk adverse in their recommendations when death is a potential outcome. 16 Previous patient surveys have also suggested that patients are often not wellinformed and perceive recommendations to be heavily weighted toward taking medication. 17 The degree to which this is the case in cancer treatment decision-making is less clear. A recent study of informed decision-making in prostate cancer indicated that patients were well-informed regarding treatment options, including the risks and benefits, but were infrequently engaged in a shared decisionmaking process. 18 Our study results suggest that patients who engage in discussions with their physicians, including prognostic assay results, will have a greater level of concordance with their physician's recommendation for treatment compared with the initial discussions in the absence of these assay results. This will lead to a meaningful and significant decrease in patient decisional conflict, with most patients feeling well informed. Also, patients believed this process provided them with an active role in their own treatment decisionmaking.
The present study had several limitations. First, our study was restricted to patients with stage II colon cancer; therefore, its applicability to other cancer patient groups is uncertain. However, the results of our study are concordant with other treatment decision-making studies involving different types of cancer. 19 The present study was also potentially limited by the uncertainties of adjuvant therapy benefit for stage II colon cancer. It is conceivable that if the benefits from chemotherapy were more clearly defined, the results would have varied. Finally, the Oncotype DX assay was validated as a prognostic, rather than a predictive, assay. Thus, it produces a score indicating the risk of recurrence that can be useful in treatment decision-making; however, the results alone do not predict the differential response to treatment.
Conclusion
The present study has demonstrated a beneficial effect of the Oncotype DX colon cancer assay as a decision-making tool that provides both physicians and patients with greater confidence in their treatment decisions when used in conjunction with providerepatient communication. The assay results also decreased patient decisional conflict and increased the concordance between the physician and patient treatment choices. Data presented as n (%). The bold figures along the diagonal denote agreement between pre-assay and post-assay patient decisions regarding treatment, while off-diagonal italicized figures indicate a change in patient treatment preference from pre-to post-assay.
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Clinical Practice Points
Whether and how aggressively to treat individual patients with stage II colon cancer remain challenging questions requiring patient-specific factors such as prognosis and patient preferences. It was previously reported in a prospective study that the Oncotype DX colon assay will lead to a change in physician treatment recommendations for 45% of patients with T3 MMR-P stage II tumors.
Our new findings also suggest that knowledge of the 12-gene assay results will further influence the treatment decisions for most patients and physicians, increase physician confidence in their own treatment recommendations, improve concordance in treatment preference between patients and physicians, and decrease patients' feelings of decisional conflict. The Oncotype DX colon cancer assay as a decision-making tool that provides both physicians and patients with greater confidence in their treatment decisions when used in conjunction with providerepatient communication. 
